UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): June 21, 2023 |
Eledon Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Delaware | 001-36620 | 20-1000967 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
19900 MacArthur Blvd. Suite 550 | |
Irvine, California | | 92612 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 949 238-8090 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Stock, $0.001 par value | | ELDN | | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Eledon Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 21, 2023 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan (the “2020 Incentive Plan”). The 2020 Incentive Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company’s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional 9,600,000 shares so that the new aggregate share limit under the 2020 Incentive Plan is 14,460,000 shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Incentive Plan from November 15, 2030 to April 26, 2033.
The preceding summary of the 2020 Incentive Plan amendment is qualified in its entirety by reference to the full text of the 2020 Incentive Plan, as amended, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Annual Meeting on June 21, 2023, the Company’s stockholders voted on four proposals described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 1, 2023. The results for each matter voted on by the stockholders at the Annual Meeting were as follows:
Proposal 1: The stockholders of the Company elected each of David-Alexandre C. Gros, M.D. and Jan Hillson, M.D. as Class III Directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2026 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal. The results of the stockholders' vote with respect to the election of the Class III Directors were as follows:
| | | | |
Nominee | Term Expiring | For | Withhold | Broker Non-Vote |
David-Alexandre C. Gros | 2026 | 7,123,958 | 419,359 | 2,272,638 |
Jan Hillson | 2026 | 7,123,987 | 419,330 | 2,272,638 |
Proposal 2: The stockholders of the Company approved an amendment to the Company's 2020 Incentive Plan, increasing the aggregate number of shares available for issuance by 9,600,000 shares. The results of the stockholders' vote with respect to the approved amendment were as follows:
| | | |
For | Against | Abstain | Broker Non-Vote |
6,190,552 | 1,098,694 | 254,071 | 2,272,638 |
Proposal 3: The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the 2023 definitive proxy statement on Schedule 14A, as follows:
| | | |
For | Against | Abstain | Broker Non-Vote |
7,051,556 | 234,105 | 257,656 | 2,272,638 |
Proposal 4: The stockholders of the Company ratified the appointment of KMJ Corbin & Company LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results of the stockholders' vote with respect to the ratification were as follows:
| | |
For | Against | Abstain |
9,624,236 | 187,115 | 4,604 |
Item 9.01 Financial Statements and Exhibits.
* Filed herewith.
† Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | |
| | | |
Date: | June 21, 2023 | By: | /s/ David-Alexandre C. Gros, M.D. |
| | | Name: David-Alexandre C. Gros, M.D.
Title: Chief Executive Officer |
